<SEC-DOCUMENT>0001193125-24-255997.txt : 20241112
<SEC-HEADER>0001193125-24-255997.hdr.sgml : 20241112
<ACCEPTANCE-DATETIME>20241112162508
ACCESSION NUMBER:		0001193125-24-255997
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20241112
DATE AS OF CHANGE:		20241112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIODESIX INC
		CENTRAL INDEX KEY:			0001439725
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				203986492
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-282939
		FILM NUMBER:		241448691

	BUSINESS ADDRESS:	
		STREET 1:		919 WEST DILLON ROAD
		CITY:			LOUISVILLE
		STATE:			CO
		ZIP:			80027
		BUSINESS PHONE:		303-417-0500

	MAIL ADDRESS:	
		STREET 1:		919 WEST DILLON ROAD
		CITY:			LOUISVILLE
		STATE:			CO
		ZIP:			80027
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>d900274d424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML><HEAD>
<TITLE>424B3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(3)<BR>Registration No. 333-282939 </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g900274g00a04.jpg" ALT="LOGO" STYLE="width:2.4675in;height:0.439192in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>62,202,399 Shares of Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Offered by the Selling Stockholders </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus relates to the
proposed resale or other disposition by the selling stockholders identified in this prospectus of up to an aggregate of 62,202,399 shares of our common stock, par value $0.001 per share. We are not selling any common stock under this prospectus and
will not receive any of the proceeds from the sale or other disposition of common stock by the selling stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders may sell
the common stock on any national securities exchange or quotation service on which the securities may be listed or quoted at the time of sale, on
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">the&nbsp;over-the-counter&nbsp;market,</FONT></FONT> in one or more transactions otherwise than on these exchanges or systems, such as privately negotiated transactions, or using a
combination of these methods, and at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined at the time of sale, or at negotiated prices. See the disclosure under the heading &#147;Plan of Distribution&#148;
elsewhere in this prospectus for more information about how the selling stockholders may sell or otherwise dispose of their common stock hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
selling stockholders may sell any, all or none of the shares of common stock offered by this prospectus and we do not know when or in what amount the selling stockholders may sell their shares of common stock hereunder following the effective date
of the registration statement of which this prospectus forms a part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq Global Market under the symbol
&#147;BDSX.&#148; On November&nbsp;11, 2024, the last reported sale price of our common stock was $1.41. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company&#148;
and a &#147;smaller reporting company&#148; under federal securities laws and as such, have elected to comply with reduced public company reporting requirements for this prospectus and the documents incorporated by reference herein and may elect to
comply with reduced public company reporting requirements in future filings. See &#147;Summary&#151;Implications of Being an Emerging Growth Company and Smaller Reporting Company.&#148; </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in our securities involves significant risks. We strongly recommend that you read carefully the risks we describe in this prospectus and in any
accompanying prospectus supplement, as well as the risk factors that are incorporated by reference into this prospectus from our filings made with the Securities and Exchange Commission. See &#147;<A HREF="#toc900274_2">Risk&nbsp;Factors</A>&#148;
on page&nbsp;2 of this prospectus</B><B><I>.</I></B><B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has
approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of
this prospectus is November&nbsp;12, 2024 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc900274_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc900274_2">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc900274_3">FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc900274_4">BIODESIX, INC.</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc900274_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc900274_6">SELLING STOCKHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc900274_7">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc900274_8">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc900274_9">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc900274_10">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc900274_11">INFORMATION INCORPORATED BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc900274_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission, (the &#147;SEC&#148;), using a
&#147;shelf&#148; registration process. Under this shelf registration process, the selling stockholders may, from time to time, sell up to 62,202,399 shares of our common stock in one or more offerings as described in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each time we or the selling stockholders offer securities, we will provide a prospectus supplement that describes the terms of the relevant
offering. The prospectus supplement also may add, update or change information contained in this prospectus. Before making an investment decision, you should read carefully both this prospectus and any prospectus supplement together with the
documents incorporated by reference into this prospectus as described below under the heading &#147;Information Incorporated by Reference.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and the selling stockholders have not authorized anyone to provide you with different information or to make any representation other than
those contained in this prospectus. You should not assume that the information in this prospectus or any supplement to this prospectus is accurate at any date other than the date indicated on the cover page of these documents or the filing date of
any document incorporated by reference, regardless of its time of delivery. The selling stockholders are not making an offer to sell, or seeking offers to buy, the securities in any jurisdiction where the offer or sale is not permitted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders may sell the common stock on any national securities exchange or quotation service on which the securities may be
listed or quoted at the time of sale, in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">the&nbsp;over-the-counter&nbsp;market,</FONT></FONT> in one or more transactions otherwise than on these exchanges or systems, such as
privately negotiated transactions, or using a combination of these methods, and at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined at the time of sale, or at negotiated prices. See &#147;Plan of
Distribution&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders may sell any, all or none of the securities offered by this prospectus and we do not know
when or in what amount the selling stockholders may sell their common stock hereunder following the effective date of the registration statement of which this prospectus forms a part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This summary highlights selected information from this prospectus and does not contain all of the information that you need to consider in
making your investment decision. You should carefully read the entire prospectus, the applicable prospectus supplement and any related free writing prospectus, including the risks of investing in our securities discussed under the heading &#147;Risk
Factors&#148; contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus. You should also carefully read the
information incorporated by reference into this prospectus, including our financial statements, and the exhibits to the registration statement of which this prospectus is a part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms &#147;Biodesix,&#148; the &#147;Company,&#148; &#147;our,&#148; &#147;us&#148; and &#147;we,&#148; as used in this prospectus, refer
to Biodesix, Inc., unless we state otherwise or the context indicates otherwise. This prospectus contains trade names, trademarks and service marks of others, which are the property of their respective owners. Solely for convenience, trademarks and
trade names referred to in this prospectus may appear without the <SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> or TM symbols. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc900274_2"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Investing in our securities involves a high degree of risk. You should carefully consider the specific risks discussed or incorporated by
reference into the applicable prospectus supplement, together with all the other information contained in the prospectus or incorporated by reference into this prospectus and the applicable prospectus supplement. You should also consider the risks,
uncertainties and assumptions discussed under the caption &#147;Risk Factors&#148; included in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2023 and in our Quarterly Reports on Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> for the periods ended March&nbsp;31, June&nbsp;30 and September&nbsp;30, 2024, and in subsequent filings, which are incorporated by reference into this prospectus. You should also read our audited consolidated
financial statements and related notes included in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2023 and our unaudited consolidated financial statements and related notes included in our
Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarterly periods ended March&nbsp;31, 2024, June&nbsp;30, 2024 and September&nbsp;30, 2024. Such annual and quarterly reports are incorporated by reference in this
prospectus. These risk factors may be amended, supplemented or superseded from time to time by other reports we file with the SEC in the future or by a prospectus supplement relating to a particular offering of our securities. The occurrence of
additional risks and uncertainties not presently known to us or that we currently believe to be immaterial could materially and adversely affect our business, financial condition and results of operations. In such case, the trading price of our
common stock could decline, and you may lose all or part of your investment. This prospectus also contains forward-looking statements and estimates that involve risks and uncertainties. Our actual results could differ materially from those
anticipated in the forward-looking statements as a result of specific factors. </I></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc900274_3"></A>FORWARD-LOOKING STATEMENTS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus includes and incorporates by reference &#147;forward-looking statements&#148; within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995 and releases issued by the SEC and within the meaning of Section&nbsp;27A of the Securities Act, and Section&nbsp;21E of the Exchange Act. All statements other than statements of historical fact are
&#147;forward-looking statements&#148; for purposes of this prospectus. In some cases, you can identify forward-looking statements by terminology such as &#147;may,&#148; &#147;could,&#148; &#147;will,&#148; &#147;would,&#148; &#147;should,&#148;
&#147;expect,&#148; &#147;plan,&#148; &#147;anticipate,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;intend,&#148; &#147;predict,&#148; &#147;seek,&#148; &#147;contemplate,&#148; &#147;project,&#148; &#147;continue,&#148;
&#147;potential,&#148; &#147;ongoing,&#148; &#147;goal,&#148; or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to achieve or sustain profitability; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our unaudited financial statements include a statement that there is a substantial doubt about our ability to
continue as a going concern, and a continuation of negative financial trends could result in our inability to continue as a going concern; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attain significant market acceptance among payers, providers, clinics, patients, and
biopharmaceutical companies for our diagnostic tests; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulties managing our growth, which could disrupt our operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to retain sales and marketing personnel, and failure to increase our sales and marketing capabilities or
develop broad awareness of our diagnostic tests to generate revenue growth; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to maintain our current relationships, or enter into new relationships, with biopharmaceutical companies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant fluctuation in our operating results, causing our operating results to fall below expectations or any
guidance we provide; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product performance and reliability to maintain and grow our business; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third-party suppliers, including courier services, contract manufacturers and single source suppliers; making us
vulnerable to supply problems and price fluctuations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of a pandemic, epidemic, or outbreak of an infectious disease in the United States (U.S.) or
worldwide, including the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on our business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">natural or <FONT STYLE="white-space:nowrap">man-made</FONT> disasters and other similar events negatively
impacting our business, financial condition, and results of operations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to offer high-quality support for our diagnostic tests, which may adversely affect our relationships with
providers and negatively impact our reputation among patients and providers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to continue to innovate and improve our diagnostic tests and services we offer;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">security or data privacy breaches or other unauthorized or improper access; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant disruptions in our information technology systems; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the incurrence of substantial liabilities and limiting or halting the marketing and sale of our diagnostic tests
due to product liability lawsuits; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to compete successfully with competition from many sources, including larger companies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">performance issues, service interruptions or price increases by our shipping carriers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cost-containment efforts of our customers, purchasing groups and integrated delivery networks having a material
adverse effect on our sales and profitability; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential effects of litigation and other proceedings; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general economic and financial market conditions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract and retain key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">current and future debt financing placing restrictions on our operating and financial flexibility;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our need to raise additional capital to fund our existing operations, develop our platform, commercialize new
diagnostic tests, or expand our operations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the acquisition of other businesses, which could require significant management attention; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the uncertainty of the insurance coverage and reimbursement status of newly approved diagnostic tests;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">future healthcare reform measures that could hinder or prevent the commercial success of our diagnostic tests;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with anti-corruption, anti-bribery, anti-money laundering and similar laws; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with healthcare fraud and abuse laws; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to develop, receive regulatory clearance or approval or certification for, and introduce new
diagnostic tests or enhancements to existing diagnostic tests that will be accepted by the market in a timely manner; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to comply with ongoing FDA or other domestic and foreign regulatory authority requirements, or
unanticipated problems with our diagnostic tests, causing them to be subject to restrictions or withdrawal from the market; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">future product recalls; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">legal proceedings initiated by third parties alleging that we are infringing, misappropriating, or otherwise
violating their intellectual property rights, the outcome of which would be uncertain; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the volatility of the trading price of our common stock; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inaccurate estimates or judgments relating to our critical accounting policies, which could cause our operating
results to fall below the expectations of securities analysts and investors; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other risks, uncertainties and factors, including those set forth under &#147;Risk Factors&#148;.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These statements relate to future events or to our future financial performance and involve known and unknown risks,
uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. In evaluating
such forward-looking statements, you should specifically consider various factors that may cause actual results to differ materially from current expectations, including the risks outlined under the heading &#147;Risk Factors&#148; contained in this
prospectus and any related free writing prospectus, and in any other documents incorporated herein or therein. Any forward-looking statement in this prospectus reflects our current view with respect to future events and is subject to these and other
risks, uncertainties and assumptions relating to our operations, results of operations, industry and future growth. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we
assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and the documents incorporated by reference may also contain estimates, projections and other information concerning our
industry and our business, including estimated market size, projected growth rates and the incidence of certain medical conditions. Information that is based on estimates, forecasts, projections or similar methodologies is inherently subject to
uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market, medical and other information from
reports, research surveys, studies and similar data prepared by third parties, industry, medical and general publications, government data and similar sources. In some cases, we do not expressly refer to the sources from which this information is
derived. In that regard, when we refer to one or more sources of this type of information in any paragraph, you should assume that other information of this type appearing in the same paragraph is derived from the same sources, unless otherwise
expressly stated or the context otherwise requires. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc900274_4"></A>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Biodesix, Inc.
(&#147;Biodesix&#148;, &#147;we,&#148; &#147;us,&#148; &#147;our&#148; or the &#147;Company&#148;) is a leading diagnostic solutions company with a focus in lung disease. By combining a multi-omic approach with a holistic view of the patient&#146;s
disease state, we believe our testing solutions provide physicians with greater insights to help personalize their patients&#146; care and meaningfully improve disease detection, evaluation, and treatment. Our unique approach to precision medicine
provides timely and actionable clinical information, which we believe helps improve overall patient outcomes and lowers the overall healthcare cost by reducing the use of ineffective and unnecessary treatments and procedures. In addition to our
diagnostic tests, we provide biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. We also recognize revenue from other
services, including amounts derived from licensing our technologies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our core belief is that no single technology will answer all
clinical questions that we encounter. Therefore, we employ multiple technologies, including genomics, transcriptomics, proteomics, radiomics, and artificial intelligence (&#147;AI&#148;) enabled informatics, to discover innovative diagnostic tests
for potential clinical use. Our multi-omic approach is designed to enable us to discover diagnostic tests that answer critical clinical questions faced by physicians, researchers, and biopharmaceutical companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have commercialized five diagnostic tests which are currently on market and we perform more than 30 assays for clinical and research use as
part of our laboratory services that have been used by over 65 biopharmaceutical customers and academic partners. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Blood-Based Lung
Tests </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have five diagnostic blood-based lung cancer tests across the lung cancer continuum of care. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I><U>Diagnosis </U></I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Nodify CDT<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> and Nodify XL2<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> tests, together marketed as our Nodify Lung<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Nodule Risk Assessment testing, assess a suspicious lung nodule&#146;s risk of lung cancer to
help identify the most appropriate treatment pathway. The Nodify CDT and XL2 tests have an established average turnaround time of one and five business days, respectively, from receipt of the blood sample, providing physicians with timely results to
guide diagnostic planning. The Nodify CDT test is a blood-based test that detects the presence of seven autoantibodies associated with the presence of tumors. Elevated levels of the autoantibodies in patients with lung nodules indicate an increased
risk of lung cancer to help identify patients that may benefit from timely intervention. The Nodify XL2 test is a blood-based proteomic test that evaluates the likelihood that a lung nodule is benign to help identify patients that may benefit from
surveillance imaging. We believe we are the only company to offer two commercial blood-based tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I><U>Treatment&nbsp;&amp; Monitoring </U></I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">GeneStrat<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> ddPCR, GeneStratNGS<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> and VeriStrat<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> tests, marketed as part of our IQLung<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> testing strategy, are used
following diagnosis of lung cancer to detect the presence of mutations in the tumor and the state of the patient&#146;s immune system to help guide treatment decisions. The GeneStrat ddPCR tumor genomic profiling test and the VeriStrat immune
profiling test have an established average turnaround time of two business days from receipt of the blood sample, and the GeneStrat NGS test has an established average turnaround time of three business days from receipt of the blood sample,
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
providing physicians with timely results to facilitate rapid treatment decisions. The GeneStrat ddPCR test evaluates the presence of actionable mutations in lung cancer. The test is covered
independent of stage and can be used multiple times per patient to monitor changes in mutation status. The GeneStrat NGS test is a broad 52 gene panel, including guideline recommended mutations that help identify advanced stage patients eligible for
targeted therapy or clinical trial enrollment. The VeriStrat test is a blood-based proteomic test that provides a personalized view of each patient&#146;s immune response to their lung cancer. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth Company and Smaller Reporting Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company&#148; within the meaning of the Jumpstart Our Business Startups Act (the &#147;JOBS Act&#148;). As an
emerging growth company, we may take advantage of certain exemptions from various public company reporting requirements, including the requirement that our internal control over financial reporting be audited by our independent registered public
accounting firm pursuant to Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, certain requirements related to the disclosure of executive compensation in our periodic reports and proxy statements, the requirement that we hold a nonbinding advisory
vote on executive compensation and any golden parachute payments, and we have taken advantage of the ability to provide reduced disclosure of financial information in this prospectus, such as being permitted to include only two years of audited
financial information and two years of selected financial information in addition to any required unaudited interim financial statements, with correspondingly reduced &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results
of Operations&#148; disclosure. We may take advantage of these exemptions until we are no longer an emerging growth company. Section&nbsp;107 of the JOBS Act provides that an &#147;emerging growth company&#148; can take advantage of the extended
transition period provided in Section&nbsp;7(a)(2)(B) of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), for complying with new or revised accounting standards. In other words, an &#147;emerging growth company&#148; can
delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have elected to
take advantage of the extended transition period to comply with new or revised accounting standards and to adopt certain of the reduced disclosure requirements available to emerging growth companies. As a result of the accounting standards election,
we will not be subject to the same implementation timing for new or revised accounting standards as other public companies that are not emerging growth companies, which may make comparison of our financials to those of other public companies more
difficult. Additionally, because we have taken advantage of certain reduced reporting requirements, the information contained herein may be different from the information you receive from other public companies in which you hold stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will remain an emerging growth company until the earliest to occur of (i)&nbsp;the last day of the fiscal year in which we have more than
$1.24&nbsp;billion in annual revenue; (ii)&nbsp;the date we qualify as a &#147;large accelerated filer,&#148; with at least $700&nbsp;million of equity securities held by <FONT STYLE="white-space:nowrap">non-affiliates;</FONT> (iii)&nbsp;the date on
which we have issued, in any three-year period, more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities; and (iv)&nbsp;until December&nbsp;31, 2025 (the last day of the fiscal year ending after the
fifth anniversary of the completion of our initial public offering). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we are a &#147;smaller reporting company&#148; as
defined in Item 10(f)(1) of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT> Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited
financial statements. We will remain a smaller reporting company until the last day of the fiscal year in which (i)&nbsp;the market value of our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $250&nbsp;million as
of the end of that year&#146;s second fiscal quarter, or (ii)&nbsp;our annual revenues exceeded $100&nbsp;million during such completed fiscal year and the market value of our common stock held by
<FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700&nbsp;million as of the end of that year&#146;s second fiscal quarter. To the extent we take advantage of such reduced disclosure obligations, it may also make comparison of our
financial statements with other public companies difficult or impossible. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated in Delaware in 2005 as Elston Technologies, Inc. Our principal executive offices are located at 919 West Dillon Rd.,
Louisville, Colorado 80027, and our telephone number is (303) <FONT STYLE="white-space:nowrap">417-0500.</FONT> On June&nbsp;20, 2006, we changed our name to Biodesix, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our website address is www.biodesix.com. Information contained on, or accessible from, or hyperlinked to, our website is not incorporated by
reference into this prospectus, and you should not consider information on our website to be part of this prospectus, or in deciding whether to purchase our securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our filings with the SEC are posted on our website at www.biodesix.com. Other than the specifically incorporated SEC filings, the information
found on or accessible through our website is not part of this or any other report we file with or furnish to the SEC. The public can also obtain copies of these filings by accessing the SEC&#146;s website at http://www.sec.gov. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc900274_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will not receive any of the proceeds from the sale of our common stock by the selling stockholders. Any proceeds from the sale by the selling stockholders
of the common stock offered by this prospectus will be received by the selling stockholders. See &#147;Selling Stockholders.&#148;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc900274_6"></A>SELLING STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus covers the resale or other disposition from time to time identified in the table below of up to an aggregate of 62,202,399 shares of our
common stock. The selling stockholders may from time to time offer and sell any or all of the Registration Shares set forth below pursuant to this prospectus and any accompanying prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the number of shares of common stock beneficially owned by the selling stockholders, the number of shares of common stock that
may be offered under this prospectus and the number of shares of common stock owned by the selling stockholders assuming all of the shares covered hereby are sold and assuming the conditions noted in the footnotes thereto. The number of shares
beneficially owned by each selling stockholder is determined under rules issued by the SEC. Under these rules, beneficial ownership includes any shares over which a selling stockholder has sole or shared voting power or investment power. In
computing the beneficial ownership and&nbsp;percentage ownership of each selling stockholder, we have deemed shares of common stock subject to options that are currently exercisable or exercisable within 60 days of October&nbsp;25, 2024 and RSUs
representing the right to receive shares of common stock that were deferred under the Director Deferred Compensation Plan or that vest within 60 days of October&nbsp;25, 2024 to be outstanding and to be beneficially owned by the person holding the
option or restricted stock unit, although these shares are not considered outstanding for purposes of computing the&nbsp;percentage ownership of any other selling stockholder. Percentage ownership is based on 145,467,295 shares of common stock
outstanding as of October&nbsp;25, 2024. The number of shares of common stock in the column &#147;Number of Shares Being Offered Hereby (Maximum Number) That May Be Sold&#148; represents all of the shares of common stock that the selling
stockholders may offer hereunder. The selling stockholders may sell some, all or none of the shares of common stock that may be offered hereunder. We do not know when the shares of common stock will be sold by the selling stockholders, and the
selling stockholders may offer the shares of common stock from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lawrence T. Kennedy, Jr. is the Managing Partner and Chief Executive Officer
of Westwood Management and has served on our Board of Directors since January 2023. Jack Schuler is a <FONT STYLE="white-space:nowrap">co-founder</FONT> of Crabtree Partners and has served on our Board of Directors since June 2008. Dr.&nbsp;Matthew
Strobeck is Managing Partner of Birchview Capital LP and has served on our Board of Directors since January 2012. John Patience is a <FONT STYLE="white-space:nowrap">co-founder</FONT> of Crabtree Partners and has served on our Board of Directors
since June 2008. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information set forth below is based upon information obtained from the selling stockholders and upon information known to us at
October&nbsp;25, 2024. Unless otherwise indicated, the address for each beneficial owner listed in the table below is c/o Biodesix, Inc., 919 West Dillon Rd., Louisville, Colorado 80027. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Beneficial</B><br><B>Ownership Prior to</B><br><B>this Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares<BR>Being Offered<BR>Hereby&nbsp;(Maximum<BR>Number)&nbsp;That&nbsp;May<BR>Be Sold</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Beneficial</B><br><B>Ownership After</B><br><B>the Sale of the</B><br><B>Maximum</B><br><B>Number&nbsp;of&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Address of Selling Stockholder</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Lawrence T. Kennedy,&nbsp;Jr.<SUP
STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,657,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,603,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,053,444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Jack
Schuler<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,181,581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,707,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">473,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Matthew
Strobeck<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,080,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,809,658</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,270,699</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with John
Patience<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,685,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,081,423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">604,299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents beneficial ownership of less than 1%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a) 24,700 shares of common stock issuable upon the exercise of options held by Mr.&nbsp;Kennedy
that are vested and exercisable within 60 days of October&nbsp;25, 2024, (b) RSUs held by Mr.&nbsp;Kennedy representing the right to receive 284,257 shares of common stock that will vest within 60 days of October&nbsp;25, 2024 and be deferred under
the Director Deferred Compensation Plan until separation from </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
service to the Company, and (c) 9,582,783 shares of common stock held by Lawrence T. Kennedy, Jr.&nbsp;Revocable Trust UAD 6/19/01 and as amended from time to time, (d) 12,267,873 shares of
common stock held by Lawrence T. Kennedy, Jr. Perpetuity Trust UAD 6/30/16, (e) 2,775,386 shares of common stock held by <FONT STYLE="white-space:nowrap">KFDI-B</FONT> LLC, (f) 722,041 shares of common stock held by Lair BDSX GRAT <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2022-03-02.</FONT></FONT> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a) 70,802 shares of common stock issuable upon the exercise of options held by Jack Schuler that
are vested and exercisable within 60 days of October&nbsp;25, 2024, (b) RSUs held by Mr.&nbsp;Schuler representing the right to receive 316,097 shares of common stock that vest within 60 days of October&nbsp;25, 2024 and be deferred under the
Director Deferred Compensation Plan until separation from service to the Company, and (c) 30,794,682 shares of common stock held by Jack W. Schuler Living Trust. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a) 36,417 shares of common stock issuable upon the exercise of options held by Dr.&nbsp;Matthew
Strobeck that are vested and exercisable within 60 days of October&nbsp;25, 2024, (b) RSUs held by Dr.&nbsp;Matthew representing the right to receive 327,783 shares of common stock that vest within 60 days of October&nbsp;25, 2024 and be deferred
under the Director Deferred Compensation Plan until separation from service to the Company, and (c) 2,542,928 shares of common stock held by Dr.&nbsp;Strobeck, (d) 2,570,879 shares of common stock held by Birchview Fund LLC, (e) 85,673 shares of
common stock held by Birchview Capital Separately Managed Account, (f) 40,665 shares of common stock held by Clajer Capital LLC and (g)&nbsp;119,003 shares of common stock held in each of four UTMA accounts for the benefit of the minor children of
Dr.&nbsp;Strobeck (for an aggregate amount of 476,012 shares). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a) 70,802 shares of common stock issuable upon the exercise of options held by Mr.&nbsp;Patience
that are vested and exercisable within 60 days of October&nbsp;25, 2024, (b) RSUs held by Mr.&nbsp;Patience representing the right to receive 316,097 shares of common stock that vest within 60 days of October&nbsp;25, 2024 and be deferred under the
Director Deferred Compensation Plan until separation from service to the Company, and (c) 2,078,298 shares of common stock held by Patience Enterprises LP, (d) 4,829,611 shares of common stock held by John Patience Living Trust, dated July&nbsp;23,
1993, and (e) 52,988 shares of common stock held by Diane Patience, and (f) 337,926 shares of common stock held directly by John Patience. Does not include 246,913 shares held by Ventana Charitable Foundation. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc900274_7"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are registering the shares of common stock issued to the selling stockholders to permit the sale, transfer or other disposition of these shares by the
selling stockholders or their donees, pledgees, transferees or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">other&nbsp;successors-in-interest&nbsp;from</FONT></FONT> time to time after the date of this prospectus. We will not
receive any of the proceeds from the sale by the selling stockholders of their shares of common stock. We will, or will procure to, bear all fees and expenses incident to our obligation to register the shares of common stock. In the event that a
selling stockholder elects to sell its shares of common stock through an underwritten offering on a firm commitment or best efforts basis, we will amend the registration statement to which this prospectus relates to disclose all relevant and
material information regarding such offering and sale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders may sell all or a portion of the shares of common stock beneficially
owned by them and offered hereby from time to time. If the shares of common stock are sold through underwriters or broker-dealers, the selling stockholders will be responsible for underwriting discounts (it being understood that the selling
stockholders shall not be deemed to be underwriters solely as a result of their participation in this offering) or commissions or agent&#146;s commissions. The shares of common stock may be sold on any national securities exchange or quotation
service on which the securities may be listed or quoted at the time of sale, in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">the&nbsp;over-the-counter&nbsp;market</FONT></FONT> or in transactions otherwise than on these
exchanges or systems or in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">the&nbsp;over-the-counter&nbsp;market</FONT></FONT> and in one or more transactions at fixed prices, at prevailing market prices at the time of the sale, at
varying prices determined at the time of sale, or at negotiated prices. These sales may be effected in transactions, which may involve crosses or block transactions. The selling stockholders may use any one or more of the following methods when
selling their shares of common stock: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ordinary brokerage transactions and transactions in which a broker-dealer solicits purchasers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">block trades in which a broker-dealer will attempt to sell the shares as agent, but may position and resell a
portion of the block as principal to facilitate the transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchases by a broker-dealer as principal and resale by the broker-dealer for its account; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exchange distribution in accordance with the rules of the applicable exchange; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">privately negotiated transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;at the market&#148; or through market makers or into an existing market for the shares;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">short sales entered into after the effective date of the registration statement of which this prospectus is a
part; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through the writing or settlement of options or other hedging transactions, whether through an options exchange
or otherwise, after the effective date of the registration statement of which this prospectus is a part; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through the distribution of the shares by any selling stockholders to its partners, members or stockholders;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through broker-dealers that agree with the selling stockholders to sell a specified number of such shares at a
stipulated price per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through one or more underwritten offerings on a firm commitment or best efforts basis; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a combination of any such methods of sale; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other method permitted pursuant to applicable law. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders also may resell all or a portion of the shares of common stock in open market transactions in reliance upon Rule 144, as permitted by
that rule, or Section&nbsp;4(a)(1) under the Securities Act, if available, rather than under this prospectus, provided that they meet the criteria and conform to the requirements of those provisions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Broker-dealers engaged by the selling stockholders may arrange for other broker-dealers to participate in
sales. If the selling stockholders effect such transactions by selling their shares of common stock to or through underwriters, broker-dealers or agents, such underwriters, broker-dealers or agents may receive commissions in the form of discounts,
concessions or commissions from the selling stockholders or commissions from purchasers of the shares of common stock for whom they may act as agent or to whom they may sell as principal. Such commissions will be in amounts to be negotiated, but,
except as set forth in a supplement to this prospectus, in the case of an agency transaction will not be in excess of a customary brokerage commission in compliance with FINRA Rule 2121; and in the case of a principal transaction a markup or
markdown in compliance with <FONT STYLE="white-space:nowrap">FINRA&nbsp;IM-2121.01.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with sales of the shares of common stock or
otherwise, the selling stockholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the shares of common stock in the course of hedging in positions they assume. The
selling stockholders may also sell their shares of common stock short and if such short sale takes place after the date that this registration statement is declared effective by the SEC, the selling stockholders may deliver their shares of common
stock covered by this prospectus to close out short positions and to return borrowed shares of common stock in connection with such short sales. The selling stockholders may also loan or pledge their shares of common stock to broker-dealers that in
turn may sell such shares, to the extent permitted by applicable law. The selling stockholders may also enter into option or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities
which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended
to reflect such transaction). Notwithstanding the foregoing, the selling stockholders have been advised that they may not use their shares of common stock the resale of which has been registered on this registration statement to cover short sales of
our common stock made prior to the date the registration statement, of which this prospectus forms a part, has been declared effective by the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
selling stockholders may, from time to time, pledge or grant a security interest in some or all of the shares of common stock owned by them and, if they default in the performance of their secured obligations, the pledgees or secured parties may
offer and sell the shares of common stock from time to time pursuant to this prospectus or any amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act, amending, if necessary, the list of selling
stockholders to include the pledgee, transferee or other successors in interest as selling stockholders under this prospectus. The selling stockholders also may transfer and donate the shares of common stock in other circumstances in which case the
transferees, donees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling
stockholders and any broker-dealer or agents participating in the distribution of the shares of common stock may be deemed to be &#147;underwriters&#148; within the meaning of Section&nbsp;2(11) of the Securities Act in connection with such sales.
In such event, any commissions paid, or any discounts or concessions allowed to, any such broker-dealer or agent and any profit on the resale of the shares purchased by them may be deemed to be underwriting commissions or discounts under the
Securities Act. Selling stockholders who are &#147;underwriters&#148; within the meaning of Section&nbsp;2(11) of the Securities Act will be subject to the applicable prospectus delivery requirements of the Securities Act including Rule 172
thereunder and may be subject to certain statutory liabilities of, including but not limited to, Sections 11, 12 and 17 of the Securities Act and <FONT STYLE="white-space:nowrap">Rule&nbsp;10b-5&nbsp;under</FONT> the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each selling stockholder has informed the Company that it is not a registered broker-dealer and does not have any written or oral agreement or understanding,
directly or indirectly, with any person to distribute the shares of common stock. Upon the Company being notified in writing by a selling stockholder that any material arrangement has been entered into with a broker-dealer for the sale of common
stock through a block trade, special offering, exchange distribution or secondary distribution or a purchase by a broker or dealer, a supplement to this prospectus will be filed, if required, pursuant to Rule 424(b) under the Securities Act,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
disclosing (i)&nbsp;the name of each such selling stockholder and of the participating broker-dealer(s), (ii) the number of shares of common stock involved, (iii)&nbsp;the price at which such
shares of common stock were sold, (iv)&nbsp;the commissions paid or discounts or concessions allowed to such broker-dealer(s), where applicable, (v)&nbsp;that such broker-dealer(s) did not conduct any investigation to verify the information set out
in this prospectus, and (vi)&nbsp;other facts material to the transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the securities laws of some U.S. states, the shares of common stock may
be sold in such states only through registered or licensed brokers or dealers. In addition, in some U.S. states the shares of common stock may not be sold unless such shares have been registered or qualified for sale in such state or an exemption
from registration or qualification is available and is complied with. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There can be no assurance that any selling stockholder will sell any or all of the
shares of common stock registered pursuant to the shelf registration statement, of which this prospectus forms a part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each selling stockholder and any
other person participating in such distribution will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including, without limitation, to the extent applicable, Regulation M of the Exchange Act, which
may limit the timing of purchases and sales of any of the shares of common stock by the selling stockholder and any other participating person. To the extent applicable, Regulation M may also restrict the ability of any person engaged in the
distribution of the shares of common stock to engage in market-making activities with respect to the shares of common stock. All of the foregoing may affect the marketability of the shares of common stock and the ability of any person or entity to
engage in market-making activities with respect to the shares of common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will pay all expenses of the registration of the shares of common
stock, including, without limitation, SEC filing fees and expenses of compliance with state securities or &#147;blue sky&#148; laws; provided, however, that each selling stockholder will pay all underwriting discounts and selling commissions, if any
and any related legal expenses incurred by it. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc900274_8"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the securities being offered hereby will be passed upon for us by Sidley Austin LLP, San Francisco, California. Partners of
Sidley Austin LLP own less than 1% of our outstanding common stock. Additional legal matters may be passed upon for us or any underwriters, dealers or agents, by counsel that we will name in the applicable prospectus supplement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc900274_9"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements of Biodesix, Inc. as of December&nbsp;31, 2023 and 2022, and for the years then ended, have been incorporated by
reference herein in reliance upon the report of KPMG LLP, independent registered public accounting firm, incorporated by reference herein, and upon the authority of said firm as experts in accounting and auditing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc900274_10"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act of 1933, as
amended (the &#147;Securities Act&#148;), with respect to the securities offered by this prospectus and any applicable prospectus supplement. This prospectus and any applicable prospectus supplement do not contain all of the information set forth in
the registration statement and its exhibits and schedules in accordance with SEC rules and regulations. For further information with respect to our Company and the securities being offered by this prospectus and any applicable prospectus supplement,
we refer you to the registration statement, including its exhibits and schedules. Statements contained in this prospectus and any applicable prospectus supplement, including documents that we have incorporated by reference, as to the contents of any
contract or other document referred to are not necessarily complete, and, with respect to any contract or other document filed as an exhibit to the registration statement or any other such document, each such statement is qualified in all respects
by reference to the corresponding exhibit. You should review the complete contract or other document to evaluate these statements. You may obtain copies of the registration statement and its exhibits via the SEC&#146;s website at http://www.sec.gov.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and current reports, proxy statements and other documents with the SEC under the U.S. Securities Exchange Act
of 1934, as amended (the &#147;Exchange Act&#148;). The SEC maintains a website that contains reports, proxy and information statements and other information regarding issuers, including us, that file electronically with the SEC. You may obtain
documents that we file with the SEC at http://www.sec.gov. We also make these documents available on our website at www.biodesix.com. Our website and the information contained or accessible through our website is not incorporated by reference in
this prospectus or any prospectus supplement, and you should not consider it part of this prospectus or any prospectus supplement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc900274_11"></A>INFORMATION INCORPORATED BY REFERENCE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SEC rules permit us to incorporate information by reference in this prospectus and any
applicable prospectus supplement. This means that we can disclose important information to you by referring you to another document filed separately with the SEC. The information incorporated by reference is considered to be part of this prospectus
and any applicable prospectus supplement, except for information superseded by information contained in this prospectus or any applicable prospectus supplement itself or in any subsequently filed incorporated document. This prospectus and any
applicable prospectus supplement incorporate by reference the documents set forth below that we have previously filed with the SEC (Commission File <FONT STYLE="white-space:nowrap">No.&nbsp;001-39659),</FONT> other than information in such documents
that is deemed to be furnished and not filed. These documents contain important information about us and our business and financial condition. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1439725/000095017024023513/bdsx-20231231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the year ended December&nbsp;31, 2023, filed with the SEC on March&nbsp;1, 2024; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the periods ended March&nbsp;31, 2024,
June&nbsp;30, 2024 and September&nbsp;30, 2024, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1439725/000095017024055651/bdsx-20240331.htm">May&nbsp;
8, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1439725/000095017024092773/bdsx-20240630.htm">August&nbsp;
7, 2024</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1439725/000095017024119792/bdsx-20240930.htm">November&nbsp;1, 2024</A>, respectively; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Current Reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1439725/000119312524090787/d779805d8k.htm">April&nbsp;9,
 2024</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1439725/000119312524145965/d832577d8k.htm">May&nbsp;23, 2024</A>; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the information specifically incorporated by reference into our Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> from our Definitive Proxy Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1439725/000119312524118069/d674951ddef14a.htm">Schedule 14A</A>, filed with the SEC on April&nbsp;26, 2024; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The description of our common stock contained in our Registration Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1439725/000119312520275716/d94177d8a12b.htm">Form
 <FONT STYLE="white-space:nowrap">8-A</FONT></A>, dated October&nbsp;26, 2020. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All documents that we file (but not
those that we furnish) pursuant to Section&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act, after the date of the initial registration statement of which this prospectus is a part and prior to the effectiveness of the registration statement shall
be deemed to be incorporated by reference into this prospectus </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and will automatically update and supersede the information in this prospectus, and any previously filed documents. All documents that we file (but not those that we furnish) pursuant to
Section&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act on or after the date of this prospectus and prior to the termination of the offering of any of the securities covered under this prospectus shall be deemed to be incorporated by reference
into this prospectus and will automatically update and supersede the information in this prospectus, the applicable prospectus supplement and any previously filed documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any statement contained herein or in a document incorporated or deemed to be incorporated by reference in this prospectus or any applicable
prospectus supplement shall be deemed to be modified or superseded for purposes of this prospectus and such applicable prospectus supplement to the extent that a statement contained in this prospectus or such applicable prospectus supplement, or in
any other subsequently filed document which also is or is deemed to be incorporated by reference in this prospectus and such applicable prospectus supplement, modifies or supersedes such earlier statement. Any statement so modified or superseded
shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus or such applicable prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You can obtain any of the filings incorporated by reference into this prospectus or any applicable prospectus supplement through us or from
the SEC through the SEC&#146;s website at http://www.sec.gov. Upon request, we will provide, without charge, a copy of any or all of the reports and documents referred to above which have been incorporated by reference into this prospectus or any
applicable prospectus supplement. Prospective investors may obtain documents incorporated by reference in this prospectus or any applicable prospectus supplement by requesting them in writing or by telephone from us at our executive offices at: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Biodesix, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">919 West Dillon
Road </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Louisville, Colorado 80027 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT STYLE="white-space:nowrap">(303)&nbsp;417-0500</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our reports and documents incorporated by reference herein may also be found in the &#147;Investor Relations&#148; section of our website at
www.biodesix.com. The content of our website and any information that is linked to or accessible from our website (other than our filings with the SEC that are incorporated by reference, as set forth under &#147;Information Incorporated by
Reference&#148;) is not incorporated by reference into this prospectus or any applicable prospectus supplement and you should not consider it a part of this prospectus, any applicable prospectus supplement, or the registration statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g900274g00a04.jpg" ALT="LOGO" STYLE="width:2.4675in;height:0.439192in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>62,202,399 Shares of Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Offered by the Selling Stockholders </B></P>
<P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>November&nbsp;12, 2024 </B></P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g900274g00a04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g900274g00a04.jpg
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M*"@H*"C_P  1" "$ N0# 2(  A$! Q$!_\0 '  !  ,! 0$! 0
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MTI_6+B/TV3WJ+)RAX;>P2G+Q'=RK:[G*R6R\XEN/RK0P5@IZ<21-F;K-:[6
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M$1$(7\RQLEC?'(T.8\%KFD9@@[PLR8_PW)AK$,U+D?!)#WRG>>+"=W6-Q_\
M:TZH[CG#$&*;*^EDR94QYOIY2/(=SY'<?_2Y<VX67BM!XN+X?,-/PLP*Z-!V
M)N_4TMAJW_.19RTQ)WM\YO8=O:>A5#<Z"IM=?-1UT3HJB%VJ]I_QM'-?MHN$
M]JN5-74;M6>!X>T_ \CN4+38I0HJEU%.'GED1Z<UK99YTNX9^0\0FJIF:M#7
M$R, &QC_ #F_$=?)7KAV[T]\LU+<:0_-S,S+<]K7<6GF#L7BQQA]F),.U-"0
M!/EWR!Q\V0;O7N/(J9PV@G#$:5M=3?!F=1^^JRXIWHCQ3\@WSP2KDRM]:0QY
M)V1O\UWP/_I0>:)\$TD4S"R2-Q:YIW@C80OX4(-BDBGF?3RB1FH6P54^FS"9
MJ(!?Z&/.6(!M4UH\IG!_9N/++H7:T18K^7+-X!629W"B:&DD[9(]P=UC<>SI
M4\D8V2-T<C0YC@6N:X9@@\"ILG!/3VQ8E2Y:'Y'^%D!?>AJIJ&LAJJ20QSPO
M#V/&\$*7:3,&R89N9GI6.=:JAQ,3M_>S]@_#I'45"E"19(LT,E-(6/R(6H<#
MXE@Q/9(ZN(M;4-\2HB!\A_[CO"D! ((.T%98PEB.MPS=6UE"[,'Q98G'Q9&]
M!^!X+1>%,3V[$U$)[?*.^ ?.0..3XSS'1SW*5KKISPO$VU3 QYL\?/U4$Q[H
MM;5/DK\-!D4QS<^D)R:X_D'@>6[J7?T3X5?AVR.GK8]2XU9#I =\;1Y+?B>O
MDIPB]V0#=6(\-@CG\0P6/R[HB(NE?1$1"%B[2G]8N(_39/>HLI3I3^L7$?IL
MGO463E#PV]@E.7B.[E77W+?TDO7HC?VPM'K+_<YWNV67$5S==Z^GHF3TS61N
MG>&-<[6!RS.Q:/COMIDCUX[I0/9]IM0PCWI?Q-CM^3;HMW#G-W(%UT5\JNHA
MI*66IJI&Q01,+Y'O.0:T#,DJ+WW2-A2RQ.=5WNDD>/\ ZJ9XF>3T9-SR[<EG
M[2EI6K<8,=;[?&^ALP.9C)^<GRW%^6P#\D>L[,H::AEG=I8=5)/61PC6YZ*,
MZ2<2G%F,*^Z#6%.YW>Z=I\V)NQOKWGF2HRB#;N32Q@8T-;H$N.<7N+CJ5/-"
M%B=?-(EMS;K4]$?#)3T!GD_]6JM?*M=!."WX6PP:JOCU+I<<I)&N&V-@\EG7
MM)/,Y<%926,0G$TQV=!DF&@A,46>IS7ENW]55OYE_P"R5@];PNW]55OYE_[)
M6#U?P;1_M]U3Q75ONBTKW+OT0NOIQ^[8LU+2O<N_1"Z^G'[MBM8G_;GV5;#N
M./=7*J.[J"R.FM=JO43<_!I'4TI'V7;6D\@01_>5XKEXGLM/B&P5UJK!\S51
MEA/%IWAPY@Y'L2_33;F5KUN5$6]C+%AE?W!*^">.:%Q;)&X/:X<"#F"O;B"T
M5=AO-7;+C&8ZFF>6.' ]!'(C(CD5STW@APN-$K$%IL5N+!]\@Q)AJWW6F(U:
MB(.<T>8_<YO8<PNPLE:(M)$V"JN2EK&/J+-4.UI(V^5$[=KM[-XXY#H6F[!B
MJQX@IVRVBZ4M0'#/4#P'MZVG:.T)6JZ-\#S8?#R3)2U39FC/-=I?DCVQL<^1
MP:QHS<XG( =*\=QNUNMD!FN-?2TL0&9=-*U@]I5!:8=+L-UHIK'A9[S2RC4J
M:P@M[XWBQ@.W(\2=^[=OBIZ62=UFC+JI)ZAD+;N.?15II(OXQ+C6ZW.,DP22
MZD/YMHU6GM S[5&D7ZUI<X-:"7$Y #BFUC0QH:- EASB]Q<=2K/[G6R.N>/F
M5KFYP6V)TSCPUW#5:/:3_=6JE M"^#W82PC&VK9JW*M(GJ<][=GBL[![25/4
MKU\XFF)&@R3'10F*( ZG-4;W45G=+;+/>(VYB"1U-(1T/&;?:T^M9W6XL86&
M#$N&Z^T5) 94QEK7Y9ZCQM:[L(!6*;Q;:JSW2JM]PB,553/,<C#TCHY'>#T%
M:N%3!\6[.H^BS,2A+9-OD5Y89'PRLEB<6R,<'-<-X(V@K:.CC%4&+\+4MQB<
MWPD 1U,8WQR@;1U'>.16+%(\"XQNF#;MX9:Y 6/R;-3O\B9O0>?0=X]:GKJ3
MQ#,M1HH:.I\._/0K:Z*O,):7L+WZ%@J*QMKK"/&AJW!K<^3_ "2/4>2FL=XM
MLC ^.XT;F'SFSM(]Z6GPR1FSA9,#)6/%VFZ\N-/H=?O0)_NW+#JV/CS%=@I\
M+7B"6]6\3RT<T;(A.USW.+'  -!SWK'"W,(:0QUPL?%' N;8HM5=SA]6\?I<
MOP655JKN</JWC]+E^"DQ7@>ZCPSC>RM!9][J2U.%39+NQN;7,?22.Z"#K-][
M_4M!**Z3\,_A7@ROMS /"@._4Q/"5NT#MVM[5B4<NYF:XZ+8JHM[$YHU6+U(
M-']]&&\8VJZOS[U!,.^Y;^]N!:[_ *25P98WQ2OCE:YDC"6N:X9$$;P5_*;'
M-#VEIT*66N+2'#4+>\$L<\,<T+VR12-#F/:<PX':"%_:S)HDTNOPW31V?$+9
M*BU-V0S,VO@'1EYS?:.>Y:$L>);+?86R6BYTE4",]5D@UAUMWCM"5*BDD@=8
MC+JF6GJF3MN#GT771%Q[SBBQV6-SKK=J*FR\U\HUCU-WGL"K-:7&P"L%P:+D
MKL(J7OVGNTT]PIX++12U=-WUHGJ9<V#4S\;4;O)RW9Y=2N6"6.>".:%X?%(T
M/8YNYP(S!"EEIY(@"\6NHXYV2DAAO9?VB*M--N/JG!E!;H[28C<JF77U9&ZS
M1$WRLQS) ]:YBB=,\,;J5[+(V)I>[0*RT52X0TXV"Z1LBOK7VFKW%Q!?"X\G
M#:.T;.E6;;+O;KI$)+97TM6P\8)6O]Q74L$D1L]MEY'-'*+L-U[57>DG1=:,
M545144=/%1WH-+HYXQJB1W1(!L.?3O'L5B*'X[T@V7"5OG?/5PSW -/>J.-X
M<]SN&8'DCF44YD#QNM5Y,(RP[W18WD8Z*1T<C2U[26N!X$+^5_<\KYYY)9#F
M^1Q>X]))S*_A.*55ICN8:Q\N#KC2O)+8*TEO(.8W9ZP?6KB51=S-;WTV!ZNK
MD:0*NL<6<VM:&Y^O6]2MU*5=;Q#[=4ST=]PVZR?W1'UFUGYB']E5JK*[HCZS
M:S\Q#^RJU3+2<!G8)?J>,_N5/] GUJV3JG^XD6NUD30)]:MDZI_N)%KM8F+\
M8=ON5KX7P3W^P1$5>:9L>LP?8N\43VF\UC2V!N_O3=QD(Y<.D]16?%&Z5P8W
M4J_)(V-I>[0* =T+I [X^3"UHF\1I_G\K#O/"('EO/8.E4.OZD>^61TDCG/>
MXESG..9).\DK\8USWM8QI<YQR  S)*;*>!L# QJ6)YG3/+W+J86L-;B6^4MK
MMK-:HG=EF?)8WBYW(!?&_6BLL5WJK9<HC%54SRQXX'H(Z01D0>@K4FA7 3<(
MV+PJOC'RU6M#IB=\3-XC'O//J"\.G; /X2V?Y7MD6=WHF'-K1MGB&TMYD;2.
MT<0J(Q-IGV/\=+^OX5PX>X0[?^73T66EHGN>L?\ A=.S"]WF_G$+?YC(X^6P
M;X^L<.6S@L[+ZTE3-1U4-32RNBGA>'QR,.1:X',$*[4T[:B,L*J4\Y@?M!;U
M10O13C:'&F'6SO+&7.GRCJXAP=P>!]EV_P!8X*:)3DC=&XL=J$S,>)&AS="B
M(BX7:(B(0B(B$*)X]P528JI-;-L%QB&44^6_\EW2/=[\]7RSUUCKWT=S@=#,
MW=GN<.EIXA:Q7-OUCM]^HC2W2F9-'YIW.8>EIW@KAS+K&Q'"&5?]1F3_ )'O
M^536A;%'R9=76BK?E25KOFB3L9+N'Z6[KR5[JB<4:*;G;9'5%AD-= TZP9F&
MS,^#NS;R5G:/<027NS".O8^*ZTF455%(TM=GP=D>GWYH9<9%1X2^6"])4"Q&
MGKZ75<:;,+^!U[;Y1Q_S>I.K4 #R9.#NH^\<U5JUO=*"GNENJ**L9KT\["QX
M^(Y\5F+%^'JG#5ZFH:G-S1XT4N6R1AW']_-</;;-96-T&YDW[!\+M?0_RO/A
MR\5-AO%/<*,_.1.VMSV/;Q:>1"U#8[I37JU4]PHGZT$S=8=+3Q!Y@[%DQ3O1
M;C0X;KS25SB;54N\?CWIV[7'+I_](8ZV2XP;$/#/W<A^%WR/[JK[NMNI;K;Y
MJ*OB;-3RC)S3[QT'FL[8\P36X7JW/ =/;7N^:J -WY+N@^]:2BD9-$R2)[7Q
MO <US3F"#N(*_FI@BJ8'PU$3)89!JN8]N8<.@A2.;=,E?AT=:S/)PT/[R60E
M]Z*LJ*&I9444\D$[#FV2-Q:1VA7+B?1#35,CY[!5"E<=O@\V;F=CMX]J@]3H
MQQ5#(6LM[)F_:CG9D?605$6D)1EPNK@=Y"?49_1="TZ6[[21B.LCI:X#SGM+
M'^MNSV+L4NEVYUE;34]+98GNDD:TL8]SWN&>T-W;<ER+1HDOU5(WY0?3T,7G
M9O[X[L#=GM5KX0P9:L,1YT<9EJW#)]3+M>>0Z!R'M730Y:]%%B<E@]Y:WUU^
M>:DK3FT'(C/@41%*FA$1$(6+M*?UBXC]-D]ZBRT;I%T)RWJ[UUWLES:VIJI'
M2OIZIN3=8[3JO:-@Y$=JJ*]:-,76ASO";'52L'GTP[\TCI\3/+M35354+V !
MV=DM5%-*QY);DH>B]%10U=,XMJ:6>%PWB2,M/M7R;%(\Y,C>X\FDJY<*K9?P
MB[-NPK?[DX"@LMQGSXLIW9>O+)3W#>@W$UR<U]U-/:H#O[XX229<FMV>LA12
M5$4?F< I&022>5I55,:Y[VM8TN<XY  9DE: T,Z))*::"_8J@U9&9/I:)XVM
M/!\@Z>AOKZ%8.!=&.'\(ED]/":NXC_.ZC)SFG\D;F]FWFIPL6KQ/> LBR'5:
M]+A^P=N7,]$1$60M1>6[?U56_F7_ +)6#UO*XQNEM]5'&,WOB<UHZ205D7^2
M?&WXAF_YT7\2V<)D8P/VR!I]UDXG&]Y;LB^J@ZTKW+OT0NOIQ^[8JB_DGQM^
M(9O^=%_$KTT X<NV&L-W&FOE&ZDGEJ^^,:YS79MU&C/83Q!5G$9HWP$-<"<N
M:KT$3VS N:1[*SD1$NK>5;Z8M'$>,J 5EO#(KW3-RC<=@G;]AQ]QX9\]F5*^
MBJ;?634E=!)3U,+M62.1N3FGF%O-13'6 ;)C*GRN<!CJVC*.KAR;(WEGYPY'
MV+4HL0,(V),V_19U70B8[;,C]5C!!LW*U,4:$,2VM[WVKO5VIAM!B(9(!S8X
M^XE0"NPW>Z!Y;6V>X0$?Z2G>/@MV.HBD%V.!6*^"2,V<U<HDDYDD]:+WTUEN
ME4\-IK;6S./".!SC[ ICAW1#BZ\O:7V_Y/@.^6M=WO+^[Y7L7KYHXQ=S@%XR
M)[S9HNJ_&T[%H#0?HLD@F@Q%B6 L>W)]'22#:#PD>.!Z!V]"F.C_ $167"TD
M=95GY3NC<BV65N3(STL9T\SF>C)62L6LQ+;!CBTZK7I,/V#MRZ]$1$6.M5%6
M6F+1G'C"F^4+6&17R!F0SV-J&CS7'@>@]AV;K-1212NA<'L.:CEB;*TL=HL&
MW&AJK;6S4=?3R4]5$[5?%(W)S2O.MK8QP58\74PCO-('2M&4=1'XLL?4[HY'
M,<E2.)M =WI7ODP_705\.\13?-2=6?DGKS"8:?$XI!9_PGY+#FPZ2,W9F%2Z
M*37/ .*[:XBKL%P &]T<)E;^DW,+B26NOB=E+0U3#T.A</@K[9&.\INJ)8YN
MH7D1>^GLMTJ'!M/;:V4G@R!SO<%(K5HRQA<R.\6&KC:?.J (0/TR%XZ5C?,0
M%ZV-[O*"5#EJKN</JWC]+E^"@N'>Y_KYG-DQ!=8*:/>8J5ID>>6L<@/45>.$
M,-T&%++':[4)?!V.+R97ZSG..\D_N6/B-7%)'NV&YNM6@I9(W[;Q86791$6(
MMA4+IUT8RU$T^)</0&1[O&K::,;2?](T<>8[>E9_6^E6>/M#UDQ-++64)^2[
MD_:Z2)N<<AZ7,Z>8RYYK9HL2#!NY=.JRJO#R\E\6O1910$@Y@D'I"L2_Z'<7
MVE[C%0-N$ W24CP[/^Z<G>Q0ZKP]>:-Q;5VBX0$?Z2F>WWA;+)XY!=K@5D/A
MD9YFD+QFLJG-U75,Q;T%YR7P7KCME?([5CH:IYZ&Q./P7;M> L57-P%'8+@0
M=SI(C$W])V071>QN9("\#'.T%U&5J;N>,3_+6#ODRH?K5EK(BVG:Z([6'LVM
M[ H'AC0%=:ES),15\%##O,4'SLAY9^2.O:KNP=@RR81IG166D$<CP!).\ZTL
MG6[X#(<ECXC5021[#3<K4H*::-^V18*1$@ DG(!8TTKXF.*<;5];&_6I(W>#
MTW1WMI(!'6<W=JV61F,CN5;XST.X<Q"Z2HI8W6JN=M,E,!J./Y4>[U9*EA]1
M' \ND5RN@DF8&L635^L>YC@YCBUPW$'(JT[]H-Q3;W.=;O!;G"-W>I!&_+FU
M^0]1*A==@G$]"XBIL%S;EQ%,YP]8!"865$4GE<%A/@E9YFE<I]RKGQ][?6U+
MF?9,KB/5FO(NE\@W<NU1:J_6Z/!W_N72M^ \57!P;2X?N1S\Y\#HV^MV079>
MQO,!<!CW: E1M=K!^&Z_%5\@MELC+I'G-\A'BQ,XO<> '_I67A?0+>:R1DF(
M:N&W0;W11$2RGEL\4=>9ZE?.$<*6C"=N\#LM*(FNR,DCO&DE/2YW'W#@J%3B
M4<8M&;GY*]3X>]YO)D/FO9AVT4UAL=%:Z$94]+$(VY[W=)/,G,GK701$N$DF
MY6\  +!9/[HCZS:S\Q#^RJU5Y::<!8FO^.ZFOM%JDJ:1T,;1(V1@!(;D=A<"
MH+_)/C;\0S?\Z+^)-%+/$V%H+AH.:7*B&0RN(:=>B^^@3ZU;)U3_ '$BUVLW
M:']'V*+'I"M5PNMHDIZ.$2Z\ID80W.)[1L#B=Y"TBLC%'M?,"TWR^Y6IAK',
MB(<+9_A<?%N(:+"]AJKK<7Y0PM\5@/C2/.YC>9/[UC/%=_K<37VJNMR?K3S.
MV-'DQM&YK>0"N?3%A['>,K[WNCLL@LU(2VF::F$=\/&0C7WGAGN'657W\D..
M/Q$[]9A_C5W#VPP,VW.&T?49*I7.EF=LM:=D>A4#5Y=SU@#PN=F*+O%_-XG?
MS&-P\MXWR=0X<]O!<+"&A?$=7?Z6/$-":&UAVM/)W^-Q<T>:T-<3F=V?#>M0
M4E-#1TL--2Q-B@A8(XXV#(-:!D $8A7-#=W$;WU(1049+MY(+67U1$6 MM9E
MT_8!^0[D;_:HLK96/^?8T;(93[FN]AS'0J?6[[O;J6[VRIM]PB$U+4,,<C#Q
M!^/-9;ONAC%E)=ZJ"UV\UU"QY[S4">)FNWAF'.!!X'9O3!A]<US-B4V(ZK#K
M:-S7[<8N"HK@+%57@_$=/<Z,ES!XD\.>0EC.]I]X/ @+9=BNM)?+32W*VRB6
MEJ&!['#V@]!!V$=*R?\ R0XX_$3OUF'^-6EH1LV-L)UTENO-HD%DJ3K:WA$3
MN\29>4 '9Y'+(@<CTY\8BR&9N\8X;0]1FNZ!TL3MA[38^AR5V(B+"6RB(B$(
MB(A"(B(0B_-1NOKZK=?++6RVY="(A"_5"]+=II+A@ZLJ:B/.>C;WV&0;"TY@
M$=1Z$1>'15*X TT@/0K/%)$V:8,<2 >A6E@W1W:+M%WVKFK=GFMD: ?^G-$4
M+4DT#&O?9PNK:L=HI+);F45O;(VG826A\CGY=69V=0V+WHBG"?HVAK0 +!$1
M$+M$1$(1$1"$1$0A$1$(0@'> 5^!K1N:!V(B$+]1$0A$1$(1$1"$1$0A$1$(
M1$1"$1$0A$1$(1$1"$1$0A$1$(1$1"$1$0A$1$(1$1"$1$0A$1$(1$1"$1$0
MA$1$(1$1"$1$0A$1$(1$1"$1$0A$1$(1$1"$1$0A$1$(1$1"$1$0A$1$(1$1
*"$1$0A$1$(7_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
